<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0010273" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Crouzon syndrome</z:e>, an <z:hpo ids='HP_0000006'>autosomal dominant</z:hpo> condition characterized by <z:hpo ids='HP_0001363'>craniosynostosis</z:hpo>, <z:hpo ids='HP_0000520'>ocular proptosis</z:hpo> and <z:hpo ids='HP_0000272'>midface hypoplasia</z:hpo>, is associated with mutations in fibroblast growth factor receptor 2 (FGFR2) (refs 1-3) </plain></SENT>
<SENT sid="1" pm="."><plain>For example, we have identified 10 different mutations in the FGFR2 extracellular immunoglobulin III (IgIII) domain in 50% (16/32) of our <z:e sem="disease" ids="C0010273" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Crouzon syndrome</z:e> patients </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> mutations described so far for other craniosynostotic syndromes with associated limb anomalies--Jackson-Weiss, Pfeiffer, and <z:e sem="disease" ids="C0001193" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Apert</z:e>--also occur in the extracellular domain of FGFR2, as well as FGFR1 for Pfeiffer syndrome </plain></SENT>
<SENT sid="3" pm="."><plain>In contrast, only FGFR3 mutations have been reported in dwarfing conditions--<z:e sem="disease" ids="C0001080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">achondroplasia</z:e>, thanatophoric <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, and hypochondroplasia </plain></SENT>
<SENT sid="4" pm="."><plain>For <z:e sem="disease" ids="C0001080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">achondroplasia</z:e>, greater than 99% of mutations occur in the FGFR3 transmembrane domain </plain></SENT>
<SENT sid="5" pm="."><plain>We now report the unexpected observation of a FGFR3 transmembrane domain mutation, Ala391Glu, in three unrelated families with <z:e sem="disease" ids="C0010273" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Crouzon syndrome</z:e> and <z:hpo ids='HP_0000956'>acanthosis nigricans</z:hpo>, a specific <z:e sem="disease" ids="C0037274" disease_type="Disease or Syndrome" abbrv="">skin disorder</z:e> of <z:hpo ids='HP_0000962'>hyperkeratosis</z:hpo> and <z:mp ids='MP_0001188'>hyperpigmentation</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>The association of non-dwarfing and even non-skeletal conditions with FGFR3 mutations reveals the potential for a wide range of FGFR pleiotropic effects as well as locus <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> in <z:e sem="disease" ids="C0010273" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Crouzon syndrome</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Our study underscores the biologic complexity of the FGFR gene family </plain></SENT>
</text></document>